JP2022513068A5 - - Google Patents

Info

Publication number
JP2022513068A5
JP2022513068A5 JP2021526801A JP2021526801A JP2022513068A5 JP 2022513068 A5 JP2022513068 A5 JP 2022513068A5 JP 2021526801 A JP2021526801 A JP 2021526801A JP 2021526801 A JP2021526801 A JP 2021526801A JP 2022513068 A5 JP2022513068 A5 JP 2022513068A5
Authority
JP
Japan
Prior art keywords
cancer
loh
sample
tmb
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526801A
Other languages
English (en)
Japanese (ja)
Other versions
JP7623281B2 (ja
JP2022513068A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061710 external-priority patent/WO2020102674A1/en
Publication of JP2022513068A publication Critical patent/JP2022513068A/ja
Publication of JP2022513068A5 publication Critical patent/JP2022513068A5/ja
Priority to JP2024168315A priority Critical patent/JP2025000809A/ja
Application granted granted Critical
Publication of JP7623281B2 publication Critical patent/JP7623281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526801A 2018-11-15 2019-11-15 免疫療法で治療されたがん患者の応答の予測を改善する方法 Active JP7623281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024168315A JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767979P 2018-11-15 2018-11-15
US62/767,979 2018-11-15
PCT/US2019/061710 WO2020102674A1 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024168315A Division JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Publications (3)

Publication Number Publication Date
JP2022513068A JP2022513068A (ja) 2022-02-07
JP2022513068A5 true JP2022513068A5 (cg-RX-API-DMAC7.html) 2024-03-11
JP7623281B2 JP7623281B2 (ja) 2025-01-28

Family

ID=70727341

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526801A Active JP7623281B2 (ja) 2018-11-15 2019-11-15 免疫療法で治療されたがん患者の応答の予測を改善する方法
JP2024168315A Pending JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024168315A Pending JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Country Status (6)

Country Link
US (2) US12497661B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880246A4 (cg-RX-API-DMAC7.html)
JP (2) JP7623281B2 (cg-RX-API-DMAC7.html)
AU (1) AU2019379167B2 (cg-RX-API-DMAC7.html)
CA (1) CA3120200A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020102674A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116134155A (zh) * 2020-08-26 2023-05-16 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症的方法
CN111979323A (zh) * 2020-08-28 2020-11-24 深圳裕策生物科技有限公司 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统
CN112029861B (zh) * 2020-09-07 2021-09-21 臻悦生物科技江苏有限公司 基于捕获测序技术的肿瘤突变负荷检测装置及方法
JP2024516230A (ja) * 2021-04-30 2024-04-12 ジェネンテック, インコーポレイテッド がんのための治療及び診断方法並びに組成物
WO2023196390A1 (en) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Aneuploidy biomarkers associated with response to anti-cancer therapies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69933661T3 (de) * 1998-04-15 2012-01-26 Merck Serono Biodevelopment Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
EP3327148B1 (en) * 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
KR20170080697A (ko) * 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
MX381241B (es) 2015-04-27 2025-03-12 Cancer Research Tech Ltd Composición de células t para usarse en el tratamiento del cáncer.
US10563266B2 (en) 2015-07-14 2020-02-18 Personal Genome Diagnostics Inc. Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US11725247B2 (en) * 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2017151524A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods and systems for evaluating tumor mutational burden
US20190247435A1 (en) 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
US11332530B2 (en) 2016-09-23 2022-05-17 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
US20190240257A1 (en) 2016-10-13 2019-08-08 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
US11634777B2 (en) * 2017-01-13 2023-04-25 The General Hospital Corporation Resistance to checkpoint blockade therapy
EP3601355A1 (en) * 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy

Similar Documents

Publication Publication Date Title
JP7851982B2 (ja) 癌のための個別化ワクチン
Iacono et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study
US20220119796A1 (en) Methods of capturing cell-free methylated dna and uses of same
Reon et al. Expression of lncRNAs in low-grade gliomas and glioblastoma multiforme: an in silico analysis
Oyama et al. Isolation of a novel gene on 8p21. 3–22 whose expression is reduced significantly in human colorectal cancers with liver metastasis
Schweiger et al. The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations
US20140134158A1 (en) Kras mutations and resistance to anti-egfr treatment
Nome et al. Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing
JP2023518416A (ja) 単一細胞の進化を追跡するためのシステム及び方法
Nome et al. High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants
Trier Maansson et al. Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients
Myung et al. TERT promoter mutations and tumor persistence/recurrence in papillary thyroid cancer
KR101838394B1 (ko) 뇌실하 영역의 돌연변이 유전자를 이용한 교모세포종 조직 기원의 예측 방법 및 동물 모델
Noh et al. Targeted liquid biopsy using irradiation to facilitate the release of cell-free DNA from a spatially aimed tumor tissue
EP2714071B1 (en) Individualized vaccines for cancer
JP2024529192A (ja) 組織損傷を検出するための循環無細胞メチル化dnaの使用
Koh et al. Detection of a distinctive genomic signature in rhabdoid glioblastoma, a rare disease entity identified by whole exome sequencing and whole transcriptome sequencing
KR20150132206A (ko) 예측성 바이오마커에 대한 검정법
CN105506155A (zh) 检测长链非编码rna loc284454表达量的试剂的应用
Xu et al. A pan-cancer analysis of cystatin E/M reveals its dual functional effects and positive regulation of epithelial cell in human tumors
Wang et al. Oncogenes expand during evolution to withstand somatic amplification
CN110951915A (zh) 一种慢性乙型肝炎抗病毒治疗应答疗效预测的引物以及试剂盒
Becker et al. Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues
KR102083956B1 (ko) 다발성 골수종 환자에서 레날리도마이드 및 덱사메타손의 치료에 대한 예후 예측용 바이오 마커
Zhou et al. Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers